Evidence map›Paper›PMID 42988867›Full record

ArticleExperimental & molecular medicine2026

Pericyte-derived exosomal hexokinase 2 promotes retinal neovascularization via non-metabolic ELK3 upregulation.

Wen Zhou, Mai Peng, Ni Shen, Zhe Zhou, Jianjun Jia, Zheng Nie, Mengzhu Wang, Yongxuan Liu, Huimin Zhu, Lin Zhang and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Wen Zhou *Department of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Mai Peng *Department of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Ni Shen *Department of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Zhe Zhou *Department of Ophthalmology, PLA Naval Medical Center, Shanghai, China.
Jianjun JiaDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Zheng NieDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Mengzhu WangDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Yongxuan LiuDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Huimin ZhuDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Lin ZhangDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Min ZhaoDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Hao ZengDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Yukun ZhouDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Jiawei ZhaoDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China.
Yuxin JiangDepartment of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xi ShenDepartment of Ophthalmology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. carl_shen2005@126.com.
Xudong WenDepartment of Gastroenterology, Chengdu Integrated TCM and Western Medicine Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, China. xudongwen@cdutcm.edu.cn.
Wei ShenDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China. shenwei@smmu.edu.cn.
Hongyuan SongDepartment of Ophthalmology, Shanghai Changhai Hospital, Shanghai, China. hongyuansong@hotmail.com.ORCID http://orcid.org/0000-0001-8187-2799

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82171081, 82571241National Natural Science Foundation of China (National Science Foundation of China) 82271106National Natural Science Foundation of China (National Science Foundation of China) 82474299National Natural Science Foundation of China (National Science Foundation of China) 82571217Shanghai Science and Technology Development Foundation (Shanghai Science and Technology Development Fund) 22ZR1478200
6 · The paper itself

Abstract

Retinal neovascularization (RNV) is a major cause of irreversible vision loss worldwide. Although pericyte-endothelial cell cross-talk has been implicated in RNV, the exosome-mediated mechanism underlying this interaction has remained uncharacterized. Here we found that hexokinase 2 (HK2) expression was upregulated in pericytes under hypoxic conditions both in vitro and in vivo. Hypoxic pericytes released exosomes enriched in HK2, which promoted endothelial cell growth in vitro. Conditional deletion of Hk2 in pericytes reduced neovascular tuft formation in mice with oxygen-induced retinopathy, as did inhibition of exosome release with tipifarnib. Notably, exogenous exosomal HK2 restored vascular changes caused by pericyte Hk2 deletion or tipifarnib treatment. RNA sequencing analysis revealed that exosomal HK2 upregulated the ETS transcription factor ELK3 (ELK3), whose expression was elevated in vascular tufts of mice with oxygen-induced retinopathy. Both pericyte Hk2 deletion and tipifarnib treatment suppressed ELK3 expression. Mechanistically, exosomal HK2 bound to and increased mTOR activity, leading to increased ELK3 levels. These findings identify a previously unrecognized non-metabolic role for pericyte-derived exosomal HK2 in RNV and suggest it as a potential therapeutic target.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.